Bimekizumab Calms Psoriatic Arthritis in Phase 3 'BE' Trials

The dual interleukin-17 inhibitor was effective both in patients for whom TNF inhibitors failed and those who had never received a biologic disease-modifying antirheumatic drug in two trials.

Related Keywords

Boston , Massachusetts , United States , Glasgow , Glasgow City , United Kingdom , Netherlands , Denmark , Copenhagen , Køavn , Amsterdam , Noord Holland , Scotland , Ronald Van Vollenhoven , Josephf Merola , Iain Mcinnes , Van Vollenhoven , European Alliance Of Associations , European Union , University Of Amsterdam , American College Of Rheumatology , University Of Glasgow , American College , European Alliance , Medscape Medical News , Classification Criteria , Psoriatic Arthritis , Psoriasis , Biologic Therapy , Activism , Activist , Social Issues , Disease Modifying Antirheumatic Drugs Dmards , Mard Disease Modifying Antirheumatic Drug , Europe , European , Plaque Psoriasis , Rheumatoid Arthritis , A , Severity Indices ,